LAG-3 Expression Profiling Biomarker for Inflammatory Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively assess and treat chronic inflammatory diseases and dysfunctional HDL associated with the SCARB1 gene variant rs10846744, which is linked to cardiovascular disease, as they do not account for the role of LAG-3 in mediating these conditions.
Innovation Solution
LAG-3 expression profiling is used as a biomarker, combined with SCARB1 rs10846744 genotyping and HDL particle measurement, to identify individuals at risk, followed by targeted therapeutic interventions involving recombinant LAG-3 protein, anti-inflammatory agents, and cholesterol-lowering medications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If LAG-3 expression profiling is used as a biomarker for assessing chronic inflammatory diseases and dysfunctional HDL, then measurement precision and diagnostic accuracy are improved, but device complexity and assay complexity increase
Solution Approach 1:
The diagnostic approach is segmented into multiple independent components: SCARB1 rs10846744 genotyping, LAG-3 expression measurement, and HDL particle measurement. Each component can be performed separately using established molecular biology techniques, allowing the complex diagnostic process to be broken down into manageable, validated steps that can be implemented in existing laboratory infrastructure.
Solution Approach 2:
LAG-3 expression profiling serves multiple diagnostic functions simultaneously: it assesses inflammasome activity, evaluates chronic inflammatory disease risk, and characterizes HDL dysfunction. This multi-functional biomarker approach consolidates what would otherwise require separate assays into a single measurement platform, improving diagnostic comprehensiveness without proportionally increasing complexity.
2Reliability
If targeted therapeutic interventions using recombinant LAG-3 protein and anti-inflammatory agents are implemented, then treatment effectiveness is improved, but device complexity and treatment protocol complexity increase
Solution Approach 1:
LAG-3 expression profiling is performed as a preliminary screening step before initiating targeted therapy. This allows identification of patients who will benefit most from recombinant LAG-3 protein or anti-inflammatory interventions, enabling personalized treatment selection based on baseline biomarker status. The preliminary assessment ensures that complex therapies are reserved for those with confirmed LAG-3 dysregulation.
Solution Approach 2:
The treatment protocol incorporates follow-up LAG-3 expression measurements to monitor therapeutic response. This feedback mechanism allows adjustment of treatment intensity and duration based on individual patient response, optimizing effectiveness while avoiding unnecessary prolonged exposure to complex therapies. The feedback loop enables dynamic tailoring of treatment protocols to actual patient needs.
Data Source
AI summary
A method for determining whether a subject has or is predisposed to abnormal expression of inflammasomes and/or to dysfunctional HDL suitable for use in diagnosing atherosclerosis, chronic inflammatory disease, Incident Cardiovascular Disease (ICD) and other pathologies characterized by an inflammatory response. Specifically, a protein assay that measures LAG-3 can be used as a diagnostic predictor of pathologies such as infection, inflammation, chronic inflammatory disease, and coronary artery disease. The diagnostic is combined with the therapeutic use of a remediating drug for treatment.